ClinicalTrials.gg
CompletedNCT01516840Updated Jan 18, 2017

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban (Xarelto, BAY59-7939) in Deep Vein Thrombosis, sponsored by Bayer. Completed at 29 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.

Enrollment
28th of 36
60 · median 120
Started
2012
the only one that year
Phase 3
12 of 36
2 open now
Registered
7th of 36
by date
Lead sponsor
11 of 36
Bayer

Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 28th largest by enrollment, is the only one that started in 2012, is one of 12 in phase 3, and was the 7th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing rivaroxaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the occurrence and the recurrence of DVT or pulmonary embolism (PE) in Japanese patients with acute symptomatic DVT without symptomatic PE.

Read the detailed description

The general design of the trial is open label between the Rivaroxaban and the reference arm. However, there are two groups in the Rivaroxaban arm only for the initial 3 weeks. Between these two groups and in this initial period, the study is blinded.

03

Conditions studied

  • Deep Vein Thrombosis

Browse trials for

Keywords

  • acute symptomatic deep vein thrombosis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women >/= 20 years of age in patients with confirmed acute symptomatic proximal deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE)

Exclusion criteria

Exclusion Criteria:

  • Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT
  • More than 48 hours pre-randomization treatment with therapeutic dosages of anti-coagulant treatment or more than a single dose of warfarin from the onset of the current episode of DVT to randomization
  • Calculated (CLCR) \< 30 mL/min
  • Subjects with hepatic disease which is associated with coagulopathy leading to a bleeding risk
  • Active bleeding or high risk for bleeding contraindicating treatment with unfractioned Heparin (UFH) or warfarin
  • Systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Arm 2

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Active comparator
    Arm 3

    Drug: Unfractionated heparin

  • Active comparator
    Arm 4

    Drug: Warfarin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with newly onset of symptomatic venous thromboembolism (VTE)

    Time frame: Up to 12 months

  2. Number of clinically relevant bleedings

    Time frame: Up to 2 days after last dose

Secondary outcomes

  1. Number of participants with improvement in thrombotic burden

    Time frame: At week 3

  2. Number of participants with deterioration in thrombotic burden

    Time frame: Up to 12 months

  3. Number of participants with the composite of newly onset of symptomatic VTE or asymptomatic deterioration of thrombus

    Time frame: Up to 12 months

07

Study locations

29 sites
  • Toyoake, Aichi 470-1192, Japan
  • Sakura, Chiba 285-8741, Japan
  • Maebashi, Gunma 371-8511, Japan
  • Otake, Hiroshima 739-0696, Japan
  • Sapporo, Hokkaido 006-8555, Japan
  • Takarazuka, Hyogo 665-0827, Japan
  • Kahoku-gun, Ishikawa 920-0293, Japan
  • Kanazawa, Ishikawa 920-8650, Japan
  • Yokohama, Kanagawa 245-8575, Japan
  • Tsu, Mie 514-8507, Japan
  • Sasebo, Nagasaki 857-8511, Japan
  • Osakasayama, Osaka 589-8511, Japan
  • Suita, Osaka 565-8565, Japan
  • Bunkyo-ku, Tokyo 113-8655, Japan
  • Chuoku, Tokyo 104-8560, Japan
  • Itabashi-ku, Tokyo 173-8610, Japan
  • Meguro-ku, Tokyo 152-8902, Japan
  • Shinagawa, Tokyo 141-8625, Japan
  • Shinjuku-ku, Tokyo 162-8655, Japan
  • Aomori, 030-8553, Japan
  • Fukuoka, 810-0001, Japan
  • Kumamoto, 862-8505, Japan
  • Niigata, 951-8520, Japan
  • Okayama, 701-1192, Japan
  • Osaka, 530-8480, Japan
  • Osaka, 537-8511, Japan
  • Shizuoka, 424-8636, Japan
  • Tokushima, 770-8503, Japan
  • Wakayama, 640-8158, Japan
08

References and documents

Publications

  • Matsuo H, Prins M, Lensing AW, Fujinuma EW, Miyamoto Y, Kajikawa M. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Curr Med Res Opin. 2015 Jun;31(6):1057-61. doi: 10.1185/03007995.2015.1037728. Epub 2015 May 11. PubMed 25851062 ↗
  • Yamada N, Hirayama A, Maeda H, Sakagami S, Shikata H, Prins MH, Lensing AW, Kato M, Onuma J, Miyamoto Y, Iekushi K, Kajikawa M. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program. Thromb J. 2015 Jan 17;13:2. doi: 10.1186/s12959-015-0035-3. eCollection 2015. Erratum In: Thromb J. 2016 May 23;14:11. doi: 10.1186/s12959-016-0085-1. PubMed 25717286 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Dec 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2012
First posted
Jan 25, 2012
Start
Mar 2012
Primary completionActual
Dec 2013
CompletionActual
Jan 2014
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01516840
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 25, 2012
Start date
Mar 2012
Primary completion
Dec 2013
Completion
Jan 2014
Last update
Jan 18, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion